期刊文献+

青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床研究 被引量:2

Artesunate united Primaquine in the treatment of delay or reconnection malaria
下载PDF
导出
摘要 目的:探讨青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床疗效。方法:将82例患者随机分成治疗组和对照组各41例。治疗组:给予青蒿琥酯和伯氨喹:青蒿琥酯首剂2.4 mg/kg i.v.,12 h后予1.2 mg/kg青蒿琥酯,随后6 d每日以1.2 mg/kg青蒿琥酯同法给予;同时加服伯氨喹片22.5 mg q.d.。对照组:给予quini max,首剂20 mg/kg,i.v.gtt,12 h后予10 mg/kg,随后每日12 h给予10 mg/kg,直至患者能口服,改口服quini max片10 mg/kg,q.8.h,疗程7 d。结果:7 d后治疗组、对照组治愈率分别为97.5%、95.1%;28 d治疗组、对照组治愈率分别为97.5%、90.2%,治疗组与对照组变化相近(P>0.05);两组的退热时间分别为28.0、51.6 h,血中疟原虫清除时间分别为30.4、59.5 h,治疗组较对照组均降低(P<0.01)。结论:青蒿琥酯联用伯氨喹治疗疟疾作用迅速,副作用小,低复燃率,且对耐奎宁株有效,可作为迁延、复发疟疾以及用奎宁等传统抗疟药治疗失败的首选方法。 AIM : To approach the clinical therapeutic effects of artesunate united Primaquine in the treatment of delay or recrudescence malaria. METHODS : 82 patients were randomly divided into two groups.Patients of the treatment group(n =41)were given an initial dose of 2.4 mg/kg artesunate i.v.,12 h later,a second dose of 1.2 mg/kg artesunate was given in the same way.For the succeeding 6 days,a daily dose of 1.2 mg/kg artesunate was given in the same manner to each patient in the treatment group;and each of the patients were given Primaquine tables 22.5 mg/d,p.o..The control group(n =41)were given an initial dose of 20 mg of quinimax i.v.,12 h later,a second dose of 10 mg/kg quinimax was given in the same way.Thereafter,10 mg/kg of quinimax was given q.12.h.In the same manner until the patients could take medicines by mouth.Quinimax tablets in a dose of 10 mg/kg were then given q.8.h.The course of treatment was 7 d. RESULTS :After 7 and 28 d,the cure rates in the treatment and control group were 97.5 %,95.1 %;97.5 %,90.2 %,respectively.The changes in the treatment and control group were similar(P 0.05).The defervescence time was 28.0 and 51.6 h,and the clearing time of haemoplasmodium was 30.4 and 59.5 h in the treatment and control group,respectively;the differences was significant(P 0.01). CONCLUSION : Artesunate united Primaquine was found to act more quickly in the treatment of pernicious delay or recrudescence malaria,low recurrence rate,with only mild side effects.It is also effective in the treatment of malaria caused by quinine-resistant strains of malaria parasites.It should be the drug of first choice in the treatment of malaria that quinine fails to effect a cure.
出处 《中国临床药理学与治疗学》 CAS CSCD 2011年第1期98-100,共3页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 青蒿琥酯 伯氨喹 QUINIMAX 疟疾 Artesunate Primaquine Quinimax Malaria
  • 相关文献

参考文献6

  • 1郭燕,王俊,陈正堂.青蒿素类药物的药理作用新进展[J].中国临床药理学与治疗学,2006,11(6):615-620. 被引量:45
  • 2WHO division of control of tropical disease. Severe and complicated malaria [J]. Trans Ray Soc Med Hyg,1990,84(Suppl 2) :1-65.
  • 3孙志伟,单承启,李国福,焦岫卿,刘光裕,丁德本,王京燕.复方蒿甲醚和组份之一本芴醇两种剂型治疗恶性疟疾临床对比试验[J].中国临床药理学与治疗学,1999,4(1):21-24. 被引量:3
  • 4Pradines B. Antimicrobial agents and chemotherapy [J].Trop Med Parasitol,1999,43(2):418-420.
  • 5Krishna S, Woodrow CJ, Staines HM, et al. Reevaluation of how artemisinins work in light of e merging evidence of in vitro resistance[J]. Trends Mol Med,2006,12(5) :200-205.
  • 6Mantilla G, Oliveros H, Barnston AG. The role of ENSO in understanding changes in Colombia's annu al malaria burden by region, 1960-2006[J].Malar J,2009,8:6.

二级参考文献32

  • 1廖琳,刘佩娜,陈静科,陈静先,马莹.双氢青蒿素对阴道毛滴虫作用的体外试验研究[J].四川大学学报(医学版),2005,36(1):140-141. 被引量:5
  • 2王俊,周红.青蒿素对CpG DNA攻击小鼠保护作用的实验研究[J].中国临床药理学与治疗学,2005,10(3):290-293. 被引量:10
  • 3刘玮,周红,丁国富,鲁永玲,王良喜,罗平.小剂量CpG ODN预处理对细菌脓毒症小鼠的保护作用及其机制探索[J].中国临床药理学与治疗学,2005,10(3):314-317. 被引量:2
  • 4Aldieri E,Atragene D,Bergandi L,Riganti C,Costamagna C,Bosia A,et al.Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation[J].FEBS Lett,2003;552:141-4
  • 5Eckstein-Ludwig U,Webb RJ,Van Goethem ID,East JM,Lee AG,Kimura M,et al.Artemisinins target the SERCA of Plasmodium falciparum[J].Nature,2003;424:957-96
  • 6Ridley RG.To kill a parasite[J].Nature,2003;424:887-9
  • 7Efferth T,Olbrich A,Bauer R.mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate,arteether,and artemether[J].Biochem Pharmacol,2002;64:617-23
  • 8Beekman AC,Wierenga PK,Woerdenbag HJ,Van Uden W,Pras N,Konings AW,et al.Artemisinin-derived sesquiterpene lactones as potential antitumour compounds:cytotoxic action against bone marrow and tumour cells[J].Planta Med,1998;64:615-9
  • 9Chen HH,Zhou HJ,Fang X.Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro[J].Pharmacol Res,2003;48:231-6
  • 10Yamachika E,Habte T,Oda D.Artemisinin:an alternative treatment for oral squamous cell carcinoma[J].Anticancer Res,2004;24:2153-60

共引文献46

同被引文献14

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部